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Twenty-five conformation-dependent monoclonal antibodies (MAbs) produced by immunization of mice with oligomeric
forms of the human immunodeficiency virus type 1 (HIV-1) envelope (env) glycoprotein were used to map exposed,
immunogenic regions on oligomeric env. Based on MAb cross-competition, reactivity with diverse env proteins, and reactivity
with a panel of gp120 mutants, seven distinct epitope clusters were identified. These include the classic CD4 binding site,
V1/V2, and V3. in addition, several novel epitope clusters, including one mapping to the N- and C-termini of gp120, were
identified. The locations of the seven epitope clusters on the gp120 core structure are proposed.
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dINTRODUCTION
Characterization of conformational epitopes on a pro-
ein is a means of both understanding the humoral im-
une response to that protein and gaining structural
nformation. Numerous studies have shown that tertiary
nd quaternary interactions are important determinants
n the antigenicity of the HIV-1 envelope protein (env).
ntibodies to conformational epitopes are prevalent in
uman immunodeficiency virus type 1 (HIV-1)-positive
uman sera and account for the majority of the neutral-
zing activity (16). Work by Steimer et al. (31) and Rich-
rdson et al. (27) has shown that antibodies to oligomeric
nv and/or to gp41 are also present and account for
ome of the neutralizing activity. Furthermore, several
tudies have demonstrated that binding to oligomeric
nv correlates with virus neutralization (9, 10, 15, 29). In
his context, we found that immunization of mice with
ligomeric env yielded a preponderance of conforma-
ion-dependent antibodies, whereas immunization with
onomeric env elicited more antibodies with specificity
or linear epitopes (8). A unique panel of 138 monoclonal
ntibodies (MAbs), including many that were specific for
ligomeric env (3), was derived from these mice. The
anel has been used for studying the folding, oligomer-
1 Present address: AIDS Research Center, The Second Research
roup, National Institute of Infectious Diseases, 4-7-1 Gakuen,
usashimurayama, Tokyo 208, Japan.
2 Present address: Department of Microbiology and Immunology, F.
dward Hebert School of Medicine, Uniformed Services University,
301 Jones Bridge Rd., Bethesda, MD 20814-4799.
3 To whom reprint requests should be addressed at Building 4, Room
v37, 9000 Rockville Pike. E-mail: pearl@niaid.nih.gov.
257zation, and intracellular trafficking of HIV-1 env (23) and
or epitope mapping of 47 anti-gp41 MAbs (7). Of the 83
p120-specific antibodies, 33 were conformation depen-
ent as defined by lack of reactivity on Western blots. To
urther examine the spectrum of antibodies elicited by
mmunization with monomeric and oligomeric forms of
nv and to determine regions of gp120 that are exposed
nd immunogenic in each form, we analyzed 25 confor-
ation-dependent anti-gp120 MAbs from this panel.
ight MAbs were not included in this analysis due to
ither low yield of antibody from hybridoma supernatants
r low affinity for env. Here we present data on the
ross-reactivity with divergent env proteins, inhibition of
D4 binding to env, competition for binding to env,
pitope mapping using a series of mutant gp120 pro-
eins, and HIV-1 neutralization of these MAbs.
RESULTS
ross reactivities of anti-gp120 MAbs with divergent
lade B env proteins
The 25 anti-gp120 conformation-dependent MAbs
sed in this study were derived from mice immunized
ith env protein from the BH8 isolate of HIV-1 (IIIB) (8).
he gp140 protein used was truncated just before the
ransmembrane domain in gp41 and was not cleaved
nto gp120 and gp41 subunits due to the introduction of
small deletion at the proteolytic cleavage site. This
rotein is secreted from cells and forms very stable
ligomeric complexes. To identify conserved structural
nd immunogenic features of gp120, we examined the
ross-reactivities of the MAbs with env proteins from
ivergent clade B isolates. For this purpose, recombinant
accinia viruses expressing full-length gp160 from eight
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258 SUGIURA ET AL.solates were used. These included env proteins from
ne X4 virus (BH8), five R5 viruses (JRFL, JRCSF, SF162,
a-L, and ADA), and two R5X4 viruses (RF and SF2) (6).
he env proteins were metabolically labeled, and the
mmune complexes that formed with the 25 MAbs were
nalyzed by SDS–PAGE. Autoradiographs of typical re-
ults are shown in Fig. 1. The MAbs were placed into
hree groups based on extent of cross-reactivity; these
re denoted A (broad cross-reactivity), B (partial cross-
eactivity), and C (no cross-reactivity). The intensities of
he bands were quantified using a Molecular Dynamics
hosphorImager. For each env protein, the amount pre-
ipitated was compared with the BH8 protein. In Table 1,
represents reactivity of .50%, 6 represents 50–25%,
nd 2 represents ,25%. Eighty percent of the MAbs
ross-reacted with at least one other env protein. All of
he MAbs in group A (except D33) reacted with all seven
ivergent env proteins. The MAbs in group B reacted
ith at least one and in some cases four other env
roteins, whereas those in group C reacted only with the
H8 env protein.
D4 blocking ability of MAbs
The CD4 binding region on gp120 has been shown to
e discontinuous, consisting of amino acids in the C2,
3, and C4 domains (4, 22). To determine whether any of
ur MAbs mapped to the CD4 binding region, a blocking
ssay was performed. Metabolically labeled gp120 was
FIG. 1. Cross-reactivities of MAbs with env proteins from clade B
solates. Metabolically labeled proteins were produced by infection of
ells with recombinant vaccinia viruses expressing full-length gp160
rom different clade B isolates of HIV-1. Cells infected with the vaccinia
irus WR vector were used as a negative control. Lysates of infected
ells were immunoprecipitated with MAbs listed at the left of the figure
nd analyzed by SDS–PAGE and autoradiography. Typical examples of
mmunoprecipitates are shown. The MAbs are separated into three
roups, A, B, and C, as indicated in the text.ncubated with two concentrations of MAb to ensure oaturation. Subsequently, a tracer amount of metaboli-
ally labeled sCD4 was added, and the complexes were
mmunoprecipitated by binding to protein A–Sepharose
nd analyzed by SDS–PAGE. Representative autoradio-
rams are shown in Fig. 2, and quantification of the data
s provided in Table 1. The anti-V3 MAb D47 (C. Broder
nd P. Earl, unpublished data), which does not block CD4
inding, was used as a control. Many of the MAbs (M12,
20, D33, D28, D60, D56, and T56 in Fig. 2) efficiently
locked sCD4 binding, whereas others (T20, T27, and
54) exhibited only partial blocking. In the latter case, the
mount of blocking ranged from 24% to 67%. This could
e due to a low affinity interaction between MAb and env
r steric hindrance. Alternatively, the MAb could induce a
onformational change in gp120 such that the affinity for
D4 is altered. Partial blocking of sCD4 binding was
bserved for a few MAbs in both A and B groups as
hown in Table 1. Therefore, groups A and B are subdi-
ided: A-I and B-I denote MAbs that fully block sCD4, and
-II and B-II denote MAbs that partially block sCD4
inding.
pitope mapping by competition
To define the relationships between epitopes recog-
ized by the MAbs, we performed a cross-competition
nalysis using the BIAcore apparatus. For this, oligo-
eric gp140 was captured on a grid via interaction with
n immobilized MAb. In most cases, the anti-gp41 MAb
50 was used for capture. Two MAbs (T52 and T54)
ound poorly to env immobilized by D50, and for these
xperiments, env was captured by MAb M12. Figure 3
hows a typical sensogram obtained in the competition
ssay. The first MAb (T22) was injected three times to
aturate its recognition site on the captured gp140. A
econd MAb was then injected, and the increase in
esonance units (RU) was determined. Three examples
f MAb2 binding are shown in Fig. 3. Injection of T27 did
ot result in an increase in RU, indicating that binding of
27 is fully blocked by binding of T22. In contrast, both
12 and D47 were not blocked by T22, indicating that
hese MAbs bind to epitopes distinct from that recog-
ized by T22. Results from the cross-competition exper-
ments are given in Table 2. The assay was performed
ith 13 of the 25 MAbs, including several from each
unctional group, as the blocking MAb (MAb 1). All 25 of
he MAbs were analyzed for the ability to be blocked
MAb 2). The results are presented in Table 2 as percent
nhibition, as defined under Materials and Methods. In
eneral, MAbs in a particular group, defined by reactivity
ith diverse env proteins and sCD4 blocking, effectively
ompeted with other MAbs in that group. This held true
or A-II, B-I, and B-II. In group A-I, however, MAbs D20
nd D33 did not exhibit complete cross-blocking with
ther members of the group. Asymmetric blocking was
bserved with MAb D20. This could be accounted for by
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259CONFORMATION-DEPENDENT MAbs TO HIV-1 gp120he topology of MAb binding or a conformational change
nduced by binding of MAb1. If the epitopes for two MAbs
re overlapping but not identical, binding of one MAb
ay obstruct binding of another, but not vice versa. MAb
33 was unusual in that it completely blocked sCD4
inding (like A-I MAbs) and yet competed with A-II MAbs
n the BIAcore assay. In contrast to groups A and B, the
ross-competition analysis suggested that MAbs in
roup C compose two epitope groups: one containing
27 and D56 (defined as C-a) and the other containing
13, T49, and T56 (defined as C-b).
Some blocking between MAbs in different groups was
lso observed. For example, A-I, B-I, and C-a MAbs
ffectively blocked each other. These MAbs all mapped
o the CD4 binding site but differed in extent of cross-
eactivity with divergent env proteins, suggesting that
hey map to overlapping epitopes on BH8 gp120. The C-b
Abs also blocked CD4 binding but did not compete
ith CD4 blocking MAbs in groups A-I, B-I, and C-a. Thus
-b defines a distinct CD4 binding site epitope on the
H8 env protein that is not conserved in env proteins
T
Cross Reactivies
Group MAb BH8 JRFL JRCSF SF
-1 M6 1 1 1 1
M12 1 1 1 1
M13 1 1 1 1
D20 1 1 1 1
D21 1 6 6 1
D25 1 1 1 1
D39 1 1 6 1
D33 1 6 1 6
-II T20 1 1 1 1
T22 1 1 1 1
T27 1 1 1 1
-I D24 1 2 2 2
D28 1 2 2 2
D35 1 6 2 1
D42 1 2 2 6
D52 1 2 2 6
D53 1 2 2 2
D60 1 2 2 6
-II T52 1 6 2 2
T54 1 1 2 2
D27 1 2 2 2
D56 1 2 2 2
T13 1 2 2 2
T49 1 2 2 2
T56 1 2 2 2
a Metabolically labeled env proteins were immunoprecipitated with M
r no reactivity.
b The ability of MAbs to inhibit binding of sCD4 was determined as
uantification of bands.rom other isolates. apitope mapping using gp120 mutants
To define specific amino acids that are important for
Ab recognition, we used a series of mutant gp120
roteins constructed by Olshevsky et al. (22). We chose
utations in each of the constant regions, including
everal that have been shown to be critical for CD4
inding. In addition, we used several gp120 molecules
ith deletions of entire variable regions (37). These pro-
eins were expressed in COS7 cells and were captured
n 96-well format using a polyclonal antibody to the
-terminus of gp120. The results are presented in Table
. Values obtained by MAb binding to mutant env pro-
eins were normalized to that obtained by binding to the
XBc2 gp120 (defined as 1.0). Values of ,0.5 were
eemed to represent a significant reduction in MAb
inding and are shaded in the table. Although some
ubtle differences are found within the A-I and B-I
roups, MAbs in both groups exhibited the pattern seen
or other CD4 binding site MAbs (12, 25, 32). Amino acids
68 and 370 in the C3 domain were critical for binding;
sCD4 Blockingb
SF2 RF ADA B-al % CD4 Blocking
1 1 1 1 100%
1 1 1 1 100%
1 1 1 1 100%
1 1 1 1 100%
1 1 1 1 100%
1 1 1 1 100%
1 1 1 1 100%
2 1 1 1 100%
1 1 1 1 67%
1 1 1 1 64%
6 1 1 1 47%
2 2 2 1 100%
2 2 2 1 100%
2 1 2 1 100%
2 1 2 1 100%
2 1 6 1 100%
2 2 2 1 100%
2 1 2 1 100%
2 6 2 2 N.T.
2 2 2 6 24%
2 2 2 2 100%
2 2 2 2 100%
2 2 2 2 100%
2 2 2 2 100%
2 2 2 2 100%
s shown in Fig. 1. 1, Strong reactivity; 6, moderate reactivity; 2, little
in Fig. 2. Percent sCD4 blocking was determined by PhosphorImagerABLE 1
a and
162
Abs a
shownmino acids 256 and 257 in C2 were also important,
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260 SUGIURA ET AL.lthough mutations of these amino acids did not com-
letely abrogate binding. As has been shown for other
D4 binding site MAbs (37), deletion of variable loops 1,
, or 3 resulted in increased binding. However, the gp120
utants used in this analysis did not allow for a distinc-
ion to be made between the epitopes recognized by A-I
nd B-I. Finally, MAb D33 did not react with gp120 that
as captured by the C-terminal antibody, implying that
he D33 epitope is, at least in part, located in the C5
egion. Mapping of D33 was achieved by capturing env
roteins on ConA-coated ELISA plates. The gp120 mu-
ant analysis identified regions in gp120 that are impor-
ant for binding of several of the other groups of MAbs.
inding of two of the A-II MAbs was dependent on amino
cid 88 in the C1 region of gp120. The B-II and C-a MAb
roups clearly mapped to the V1/V2 and V3 loops, re-
pectively, because deletion of these loops completely
brogated binding. The only group that showed no dim-
nution of binding to any of the gp120 mutants was C-b.
inding of these MAbs was enhanced .10-fold by dele-
ion of the V3 loop, suggesting that their epitope is more
ccessible in the V3-deleted env as a result of either
nmasking or an alteration in the conformation of the
rotein upon V3 loop deletion.
FIG. 2. Ability of MAbs to block sCD4 binding to env. Metabolically
mount of metabolically labeled sCD4 was added, and immune comple
ypical examples are shown. The MAb groups are indicated at the top
FIG. 3. Sensogram of BIAcore competition analysis. gp140 was cap
T22) was injected three times to ensure saturation of the gp140. Subs
re on the y-axis, time (s) on the x-axis.eutralization of HIV-1 by MAbs
Several MAbs from each group were selected and
ested for the ability to neutralize HIV-1 (NL4–3). The
oncentration of MAb yielding 50% inhibition of virus
rowth is given in Table 4. Three MAbs exhibited signif-
cant neutralization of virus. Two of these, M12 and M13,
re CD4 binding site MAbs, and one, D56, is a V3 MAb.
DISCUSSION
A goal of this study was to define conserved, confor-
ational epitopes on gp120 that are exposed and immu-
ogenic. We previously described a panel of 138 MAbs
erived by immunization of mice with monomeric or
ligomeric gp140 from the BH8 isolate of IIIB (8). In this
eport, we characterize 25 MAbs from the panel, all of
hich were specific for gp120 and exhibited conforma-
ion dependence. With one exception, all of these MAbs
ound to oligomeric env protein on the surface of HIV-1
IIIB)-infected cells (C. Broder and D. Long, unpublished
ata), indicating that the structure of the immunogens
eflected the native structure of env. Furthermore, we
ave shown that gp140 remains oligomeric after mixing
ith the adjuvant and incubation at 37°C (C. Broder and
gp120 was incubated with 0.2 or 2 mg MAb. Subsequently, a tracer
re precipitated with protein A-Sepharose and analyzed by SDS–PAGE.
he individual MAbs are indicated below.
a interactions with anti-gp41 MAb D50 on the sensor surface. MAb 1
ly, MAb 2 (T22, T27, M12, or D47) was injected. Resonance units (RU)labeled
xes wetured vi
equent
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261CONFORMATION-DEPENDENT MAbs TO HIV-1 gp120. Earl, unpublished data). We used four assays: cross-
eactivity with diverse clade B env proteins, CD4 block-
ng, cross-competition for binding to env, and binding to
panel of mutated gp120 proteins to characterize these
Abs. We found that although many of the MAbs resem-
led those described in the literature, several groups of
Abs exhibited novel characteristics. From our analy-
es, seven distinct epitope clusters were recognized. A
chematic representation of the deduced locations of
hese clusters on the gp120 structure (14) is shown in
T
Cross Competition Analysis of
CD4 Block
A-I
M12 M13 D20 D21 D39 D33 D28
M
ab
2
C
D
4
B
lo
ck
in
g
A
-1
M6 100% 94% 100% N.T. N.T. 11% 100%
M12 100% 89% 86% 100% 100% 36% 93%
M13 100% 100% 100% 199% 100% 38% 100%
D20 66% 58% 100% 72% 88% 4% 100%
D21 83% 71% 100% 100% 100% 33% 86%
D25 95% N.T. 86% N.T. N.T. 29% 86%
D39 96% 85% 83% N.T. 100% 8% 92%
D33 25% N.T. 33% N.T. N.T. 100% 33%
B
-1
D24 100% N.T. 100% N.T. N.T. 17% 100%
D28 100% 93% 100% 100% N.T. 60% 100%
D35 76% N.T. 35% 97% 100% 0% 94%
D42 98% N.T. 100% 100% 100% 8% 92%
D52 87% N.T. 100% 100% 100% 42% 84%
D53 95% N.T. 100% N.T. N.T. 43% 100%
D60 100% N.T. 100% 100% 100% N.T. N.T.
C
-a
D27 71% N.T. 51% N.T. N.T. 18% 59%
D56 76% 76% 68% 73% 88% 25% 75%
C
-b
T13 36% N.T. 0% N.T. N.T. 47% 32%
T49 32% N.T. 0% N.T. N.T. 42% 29%
T56 31% N.T. 0% N.T. N.T. 46% 31%
P
ar
tia
l
C
D
4
B
lo
ck
in
g
A
-I
I
T20 20% 16% 0% N.T. N.T. 71% 19%
T22 25% 19% 13% N.T. N.T. 63% 31%
T27 23% N.T. 0% N.T. N.T. 82% 41%
B
-I
I T52 0% N.T. N.T. N.T. N.T. N.T. 94%
T54 0% N.T. N.T. N.T. N.T. N.T. 87%
V3 D47 21% 36% 6% 32% 32% 44% 23%
CD4 bs F105 99% 91% N.T. N.T. N.T. N.T. 93%
a Cross competition was determined using immobilized gp140. MAbs
f an MAb by itself is outlined in bold.ig. 4. Three groups of MAbs, A, B, and C, were defined tased on extent of cross-reactivity with diverse clade B
nv proteins. Group A, B, and C MAbs exhibited broad,
artial, or no cross-reactivity with diverse env proteins,
espectively. These groups were then subdivided on the
asis of CD4 blocking (A and B) or cross-competition (C).
ne MAb, D33, represents a unique epitope, having
haracteristics of A-I and A-II.
Both the A-I and B-I MAbs are typical CD4 binding site
Abs, exhibiting properties similar to those described by
thers (12, 25, 32). Mutations in amino acids 368 and 370
120 MAbs Using the BIAcorea
MAb 1
Partial CD4 Blocking
F105
B-I C-a C-b A-II B-II
D42 D52 D53 D56 T49 T20 T22 T27 T52
95% N.T. N.T. 100% 33% 11% 33% N.T. N.T. 90%
78% 100% 55% 100% 21% 21% 29% N.T. N.T. 78%
N.T. 100% 100% 100% 15% 15% 46% N.T. N.T. N.T.
20% 66% 41% 100% 0% 0% 4% N.T. N.T. 27%
68% 88% 55% 100% 14% 29% 57% N.T. N.T. 68%
N.T. N.T. N.T. 100% 86% 14% 21% N.T. N.T. N.T.
94% 16% 0% 100% 0% 25% 17% N.T. N.T. 88%
N.T. N.T. N.T. 42% 25% 100% 75% 75% 100% N.T.
N.T. N.T. N.T. 100% 33% 50% 33% N.T. N.T. N.T.
93% 100% 71% 100% 30% 20% 40% N.T. N.T. 93%
N.T. 85% 100% 94% 29% 12% 0% N.T. N.T. N.T.
100% 100% 84% 100% 15% 23% 15% N.T. N.T. N.T.
N.T. 100% 69% 95% 37% 53% 58% N.T. N.T. N.T.
N.T. 100% 100% 100% 71% 86% 100% N.T. N.T. N.T.
N.T. N.T. N.T. N.T. N.T. 25% N.T. N.T. N.T. N.T.
N.T. N.T. N.T. 97% 13% 13% 0% N.T. N.T. N.T.
57% 66% 48% 100% 32% 25% 11% N.T. N.T. 64%
N.T. N.T. N.T. 32% 100% 58% 32% 21% 100% N.T.
N.T. N.T. N.T. 13% 100% 46% 38% 29% 100% N.T.
N.T. N.T. N.T. 19% 100% 46% 50% 42% 100% N.T.
29% N.T. N.T. 5% 33% 100% 71% 76% 100% 14%
52% N.T. N.T. 19% 19% 88% 100% 100% 100% 43%
N.T. N.T. N.T. 29% 18% 100% 100% 100% 100% N.T.
N.T. N.T. N.T. 63% 44% 63% 56% 44% 100% N.T.
N.T. N.T. N.T. 67% 40% 67% 53% 40% 100% N.T.
39% 35% 37% 69% 38% 19% 37% N.T. N.T. N.T.
N.T. N.T. N.T. 100% 33% 40% N.T. N.T. N.T. 100%
uped according to cross-reactivity and sCD4-blocking ability. BlockingABLE 2
Anti-gp
ing
D35
100%
100%
100%
65%
95%
100%
100%
50%
100%
100%
100%
100%
100%
100%
100%
72%
73%
53%
50%
54%
38%
44%
47%
N.T.
N.T.
26%
N.T.
are grohat directly contact CD4 (14) resulted in abrogation of
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262 SUGIURA ET AL.inding, whereas mutations in amino acids 256 and 257
esulted in an impairment of binding. Also, a pronounced
ncrease in binding to V3- deleted gp120 was observed,
robably due to increased accessibility of the CD4 bind-
ng site. Although these MAbs share characteristics of
hose mapping to the “neutralizing” face of gp120 (19, 35)
nd block binding of the neutralizing MAb F105, very few
eutralized the homologous HIV-1 (NL4–3). One possible
xplanation is that the structure of the uncleaved env
rotein used for immunization represents an early, fu-
ion-incompetent form that exists before cleavage and
hat additional neutralizing epitopes are exposed after
leavage. Consistent with this, several anti-gp41 MAbs
rom the same panel did not bind to a trimeric gp41
ragment proposed to represent the fusion-active state
33). Alternatively, lack of neutralization could be due to
ow affinity. In this regard, several groups have shown
hat affinity is an important factor in neutralization (24, 28).
A-I and B-I MAbs are distinguished from each other in
he extent of cross-reactivity with diverse env proteins
uggesting subtle differences in epitope recognition.
ata from the crystal structure of the gp120 core and
CD4 showed that there are six regions of gp120 that
ontact CD4 (14), some of which are variable among HIV
solates. Interactions with these regions could account
or differences in binding observed for the two groups of
Abs.
The A-II MAbs, like A-I, cross-reacted with seven di-
erse env proteins, indicating that their epitopes are
T
Binding of Anti-gp120 MAb
CD4 Blocking
A-I
M6 M12 M13 D20 D21 D25 D39 D33 D24 D28 D35 D
HXBc2 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.
1 88N/P 0.806 0.649 0.642 0.801 0.913 0.897 1.128 0.286 0.718 0.698 1.011 1.
102E/L 1.143 1.085 0.855 0.910 0.991 0.865 1.008 0.549 0.834 0.880 0.999 0.
113D/A 1.187 1.025 0.936 0.949 1.054 1.127 1.162 0.939 0.992 1.006 0.890 1.
117K/W 1.299 1.204 0.769 0.895 0.875 1.068 1.144 0.643 0.950 0.951 0.853 1.
2 256S/Y 1.289 0.261 0.474 0.513 0.390 0.427 0.780 0.514 0.390 0.348 0.363 0.
257T/G 0.931 0.367 0.517 0.662 0.809 0.601 1.030 0.426 0.538 0.480 0.438 0.
3 368D/P 0.000 0.000 0.000 0.008 0.000 0.009 0.008 1.054 0.000 0.000 0.006 0.
368D/E 0.000 0.000 0.006 0.013 0.000 0.012 0.221 N.T. 0.000 0.000 0.007 0.
370E/R 0.175 0.455 0.571 0.344 0.333 0.267 0.865 0.860 0.109 0.113 0.147 0.
381E/P 1.826 1.116 0.931 0.816 0.973 0.857 0.851 1.187 0.854 0.866 0.788 0.
4 421K/L 1.172 0.801 0.964 1.084 0.715 0.904 0.885 1.094 0.963 1.086 0.575 0.
427W/S 1.628 0.567 1.082 1.056 0.947 0.922 0.930 0.962 0.969 1.145 0.938 0.
457D/E 1.873 1.053 1.238 0.935 0.961 1.003 0.965 0.940 0.846 0.844 0.919 1.
5 475M/S 1.131 0.809 0.818 0.745 0.800 0.952 0.882 0.844 0.781 0.900 0.752 0.
DV1 0.787 3.198 1.368 1.354 2.260 1.362 1.325 N.T. 1.192 1.552 1.052 1.
DV1/V2 1.314 N.T. 1.521 1.538 1.464 1.152 1.102 N.T. 1.415 1.512 1.050 1.
DV3 7.908 N.T. 3.025 2.684 4.083 5.359 4.463 N.T. 2.792 3.120 4.243 4.
a An ELISA was used to determine the binding of MAbs to gp120 env
egions (C1–C5) or of deletions of entire variable regions. Values for bin
hich was set at 1.000. Numbers ,0.5 are shaded. MAbs are groupedonserved in clade B env proteins. However, they only Iartially blocked sCD4 binding to env and were com-
letely unaffected by changes in amino acids 368 and
70. Mutation of amino acid 88 near the N-terminus of
p120 almost completely abrogated binding by two of the
hree MAbs in this group. Because of the close spatial
roximity of the N-terminus of gp120 and the CD4 bind-
ng site (14), binding of a MAb could sterically impede
inding of sCD4. In addition, deletion of V1, V1/V2, or V3
esulted in increased binding of this group of MAbs to
nv. Because all three variable loops are predicted to be
n the distal side, whereas the N-terminus of gp120 is
redicted to be on the proximal side, it is unlikely that
emoval of the loops exposes the A-II binding site. An
lternative explanation is that the structure of the protein
s altered by deletion of the loops, allowing for more
fficient binding.
MAb D33 exhibited several unique properties. Like A-I
Abs, it cross-reacted with all seven diverse envs and
ompletely blocked sCD4 binding to env. However, in the
IAcore assay, it blocked A-II but not A-I MAbs. In addi-
ion, the pattern of reactivity with mutant gp120 env
roteins resembled that seen with A-II MAbs. Finally,
nlike either A-I or A-II MAbs, D33 did not react with env
hat had been captured via interactions with an antibody
o the C-terminus of gp120, implying that the C-terminus
s part of the D33 epitope. Thus both the N- and C-termini
f gp120 are involved in D33 binding. In fact, these two
egions have been shown to interact (21) and to be in
roximity in the crystallized gp120 core (see Fig. 4) (14).
utant gp120 Env Proteinsa
Partial CD4 Blocking
C A-II B-II
D53 D60 D27 D56 T13 T49 T56 T20 T22 T27 T52 T54
0 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000
2 0.812 0.818 0.962 0.899 4.245 3.353 3.835 1.047 0.271 0.188 0.704 0.704
0 0.857 0.740 0.898 0.935 3.030 2.613 2.717 0.965 0.897 0.970 1.122 1.035
3 1.267 0.850 0.973 0.826 1.269 0.991 1.023 1.308 1.405 1.561 1.439 1.509
5 1.172 0.830 1.032 0.876 5.006 3.860 3.775 1.133 1.146 1.595 1.263 1.143
0 0.445 0.354 0.747 0.803 3.623 3.042 3.223 0.626 0.534 0.721 0.742 1.066
3 0.727 0.441 0.856 0.781 4.483 4.040 4.606 1.156 1.272 1.269 0.836 1.136
9 0.028 0.021 1.079 0.909 0.753 0.729 1.320 1.393 1.279 1.178 1.023 0.715
7 0.040 0.019 0.958 0.917 1.360 1.303 1.996 1.335 1.471 1.424 1.241 1.021
3 0.224 0.169 0.792 0.723 1.334 1.282 1.960 1.459 1.850 1.846 1.310 1.629
9 1.332 0.785 0.764 0.574 1.168 1.067 1.854 1.322 1.480 1.631 1.775 2.154
2 1.131 0.702 0.899 1.610 1.721 1.478 1.835 0.971 1.165 1.046 2.197 2.510
6 1.244 0.960 0.832 1.392 1.475 1.382 1.501 1.110 1.272 1.116 1.522 2.380
5 1.255 0.842 0.906 1.232 1.323 1.423 1.627 1.117 1.305 1.117 1.482 1.610
8 1.234 0.734 0.844 1.010 2.017 2.101 2.223 1.059 1.147 1.072 1.267 1.718
3 1.587 0.756 1.256 2.234 1.951 1.905 2.289 2.525 2.904 1.875 0.201 0.536
5 1.398 0.737 0.926 1.252 1.505 1.524 1.670 2.688 2.308 2.269 0.000 0.000
1 6.244 4.666 0.052 0.027 10.282 10.716 15.904 4.218 5.584 6.637 22.000 6.363
s with mutations in single amino acids within each of the five constant
mutant env proteins were normalized to binding to wild type (HXBc2),
ding to extent of cross-reactivity and CD4 blocking.ABLE 3
s to M
B-I
42 D52
000 1.00
138 0.88
964 0.91
238 1.24
077 1.07
621 0.50
835 0.71
004 0.01
028 0.01
426 0.23
833 1.26
831 0.94
857 1.11
013 1.05
779 1.06
359 1.21
100 1.18
415 6.23
protein
ding ton addition, D33 reacted well with env on the surface of
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263CONFORMATION-DEPENDENT MAbs TO HIV-1 gp120IV-1 infected cells (D. Long and C. Broder, unpublished
ata).
The B-II MAbs showed very little cross-reactivity with
ther env proteins. In accord with this, analysis with
p120 mutants demonstrated that they mapped to the
1/ V2 loop structure. Both MAbs in this group bound
ore efficiently to gp120 lacking the V3 loop, in agree-
ent with the observations of functional interactions
etween V2 and V3 (13, 30). Also, the model of Wyatt et
l. (35) predicts that the V2 loop acts as an umbrella over
he CD4 binding site, offering an explanation for our
bservation that B-II MAbs partially block binding of
CD4 to env. In addition, the B-II MAbs were both derived
rom mice immunized with trimeric or tetrameric env,
onsistent with the model that the V1/V2 loops are ex-
osed on the oligomer.
The C group of MAbs was characterized by lack of
ross-reactivity with other env proteins and complete
CD4 blocking. However, unlike other CD4 blocking
Abs, they were unaffected by alterations in amino ac-
ds 368 or 370. These MAbs were clearly separated into
wo subgroups on the basis of both cross-blocking by
IAcore analysis and reactivity with mutant gp120 pro-
eins. The first group, designated C-a, mapped to the V3
oop by virtue of almost complete abrogation of binding
o gp120 lacking the V3 loop. In contrast to most V3
pecific MAbs, these two MAbs are conformation depen-
ent. In addition, D56 completely blocked other CD4
inding site MAbs, including F105. This blocking was
symmetrical, suggesting epitope overlap or steric hin-
rance. That the C4 domain of gp120 is involved in CD4
TABLE 4
Neutralization of HIV-1 (NL4-3)a
Group MAb mg/ml
A-I M6 .50
M12 21.0
M13 35.0
D20 .50
A-II T20 .50
T27 .50
B-I D24 .50
D28 .50
D60 .50
B-II T54 .50
C-a D56 12.5
C-b T13 .50
T49 .50
T56 .50
Anti-V3 D47 ,0.06
a The MAb concentration required to achieve 50% neutralization of
irus is given.inding (22) and has also been shown to be associated gith V3 (20, 38) suggests a possible role for C4 in C-a
Ab binding. The second group, designated C-b, was
ot mapped to any specific region of gp120 by any of the
nalyses performed here. The accessibility of the C-b
pitope was greatly enhanced by removal of the V3 loop,
uggesting a conformational change or increased expo-
ure of the epitope. Because these MAbs are not cross-
eactive with other env proteins and do not map to V1, V2,
r V3, perhaps they map to V4 and/or V5.
The three immunogens used to produce this panel
licited different types of conformation-dependent MAbs.
he three monomer-derived MAbs are classic CD4 bind-
ng site MAbs. Immunization with dimeric env resulted in
D4 binding site as well as V3-dependent MAbs. Immu-
ization with trimeric or tetrameric env elicited three
ypes of MAbs, two of which were novel. One of these
roups (A-II) mapped at least in part to the N-terminus of
p120. The second group (C-b) remains unmapped but
epresents a unique epitope in that no significant cross-
locking with any other MAbs was observed. The third
roup mapped to V1/V2, consistent with the model that
he V2 loop is situated on the exterior of the oligomer
35). We also found that the trimer or tetramer-derived
Abs exhibited the least amount of cross-reactivity with
ivergent env proteins, consistent with the idea that
ariable regions exist on the exterior of the oligomeric
omplex (18, 35).
FIG. 4. Epitope map of gp120 MAbs. The approximate locations of
he epitope clusters defined by the groups of MAbs are shown super-
mposed on the crystal structure of the gp120 core (PubMed Biomol-
cule 3D structure, MMDB Id:8098) (14). Where possible, overlapping
pitopes are shown by overlapping circles. The locations of groups A-I,
-I, A-II, B-II, and C-a were determined on the basis of binding to
utant gp120 env proteins. The location of group C-b was not similarly
dentified but is placed near V4 and V5 due to lack of overlap with other
roups and specificity for BH8 env.
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264 SUGIURA ET AL.In summary, we have described a panel of anti-gp120
Abs derived by immunization of mice with monomeric
r oligomeric gp140 env protein. At least seven immuno-
enic regions of oligomeric env are defined by these
Abs; these include the previously defined CD4 binding
ite, a conformation-dependent V3 epitope, and the
1/ V2 domains. In addition, our panel includes three
ovel groups of MAbs. One group was represented
olely by D33, which was characterized by having broad
ross-reactivity and mapping to a region of gp120 com-
rised of elements of both the N- and C-termini of gp120.
his MAb was derived from dimeric gp140 and reacted
ell with surface-expressed env. The other two groups
A-II and C-b) were derived by immunization of mice with
rimeric or tetrameric gp140. These MAbs reacted
qually well with monomeric and oligomeric env, indicat-
ng that their epitopes are exposed on the monomer but
robably are more immunogenic in the context of oligo-
eric env. Further mapping of these MAbs with addi-
ional gp120 mutants might reveal domains of gp120
xposed on the oligomeric complex.
MATERIALS AND METHODS
ells and viruses
HIV-1 env proteins were produced by infection of
S-C-1 cells (American Type Culture Collection CCL26)
ith recombinant vaccinia viruses at a multiplicity of
nfection (m.o.i.) of 10 pfu/cell. The following recombinant
accinia viruses expressing full-length gp160 from differ-
nt HIV-1 isolates were used: vSC60 (BH8) (S.
hakrabarti and B. Moss, unpublished data), vCB28
JRFL), vCB29 (JRCSF), vCB32 (SF162), vCB34 (SF2),
CB36 (RF), vCB39 (ADA), and vCB43 (Ba-L) (2). Soluble
ligomeric gp140 and sCD4 were produced by infection
ith vPE12B (8) and vCB5 (1), respectively. The gp120
as produced by coinfection with vPE6 and vTF7–3 (11).
ntibodies
A panel of 138 murine MAbs raised by immunization
ith soluble monomeric or oligomeric env was previ-
usly described (8). MAbs are named M (monomer), D
dimer), and T (trimer or tetramer) depending on the
resumed oligomeric form used for immunization. Rabbit
olyclonal sera 2144 was produced by immunizing rab-
its with denatured gp140 env protein (IIIB). MAb F105
25) was obtained from the National Institutes of Health
IDS Research and Reference Program.
etabolic labeling and immunoprecipitation
BS-C-1 cells were infected with recombinant vaccinia
iruses at an m.o.i. of 10 pfu/cell. At 4 h postinfection, the
irus inoculum was replaced with methionine-free
EM-5 (minimal essential medium and 5% FBS) contain-ng 100 mCi of [35S]methionine (Amersham)/ml and incu- uated overnight. Full-length gp160 was obtained by lysis
f cells in buffer containing 100 mM Tris–HCl (pH 8.0),
00 mM NaCl, and 0.5% Triton X-100. Soluble, secreted
orms of env or CD4 were obtained by harvesting the
edium of infected cells. Immunoprecipitations were
erformed by incubating env with 1–2 mg of MAb, 100 ml
f hybridoma supernatant, or 1 ml of polyclonal serum for
h at room temperature. Where appropriate, 4–8 mg of
abbit anti-mouse IgG (Calbiochem) were added for 30
in followed by the addition of protein A-Sepharose
Pharmacia). After 30 min of rocking, Sepharose beads
ere washed twice with 1 ml of Triton buffer (50 mM
ris–HCl, pH 8.0, 300 mM NaCl, 0.1% Triton X-100). Pro-
eins were eluted in sample buffer and analyzed by
DS-10% PAGE. Bands were quantified with a Molecular
yamics PhosphorImager (Sunnyvale, CA).
D4 blocking
To determine the CD4 blocking ability of the MAbs,
etabolically labeled gp120 and sCD4 were prepared
rom the medium of cells infected with vPE6/vTF7–3 and
CB5, respectively. An MAb (0.2 or 2 mg) was incubated
ith gp120 for 1 h at room temperature. Then a tracer
mount of [35S]methionine-labeled sCD4 was added,
nd the mixture was incubated for 30 min. The com-
lexes were incubated with rabbit anti-mouse IgG and
rotein A-Sepharose. After 30 min of rocking, the Sepha-
ose beads were washed twice with 1 ml of Triton buffer
see above). Proteins were eluted in sample buffer and
nalyzed by SDS–PAGE. Bands were quantified with a
olecular Dynamics PhosphorImager. The percent inhi-
ition of sCD4 binding was determined with the following
ormula:
Inhibition 5 1 2
~Sample CD4 band intensity
2 D20 CD4 band intensity)
~D47 CD4 band intensity
2 D20 CD4 band intensity!
3
D47env band intensity
Sample env band intensity
.
n which D20 and D47 represent CD4 blocking and non-
locking MAbs, respectively.
Ab competition assayed with the BIAcore
To measure the competition between pairs of MAbs
or binding to env protein, a BIAcore 2000 (Pharmacia
iosensor) apparatus was used. Oligomeric gp140 was
aptured on the sensor grid via interactions with one of
everal anti-env MAbs, including D50 (anti-gp41), M12, or
47 (anti-gp120). To ensure the conformational integrity
f the env, fresh gp140 was used for each cycle of
apping. The capture MAbs were coupled to the dextran
atrix of a CM5 sensor chip through free amine groupssing the manufacturer’s procedure. All analyses were
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265CONFORMATION-DEPENDENT MAbs TO HIV-1 gp120erformed with HBS running buffer (10 mM HEPES, 150
M NaCl, 3.4 mM EDTA, 0.05% P20, pH 7.4) at a flow rate
f 5 ml/min. Both purified MAbs and hybridoma superna-
ants were used at a concentration of 20 mg/ml in HBS
uffer. The following procedure was followed: env was
aptured by injecting 35 ml of gp140 (50 mg/ml). The first
Ab (MAb1) was then injected three times to saturate its
ecognition sites on the gp140. Subsequently, the second
Ab (MAb2) was injected, and binding was monitored.
he sensor surface was regenerated by injection of 2.5
M HCl, pH 2.5. Based on the theory of real-time bio-
olecular interaction analysis (5), we used the index
alue of mole ratios (MR) to evaluate the epitope map-
ing data. The following formula (1) was used:
MR 5 DRU MAb/DRU gp140 3 MW MAb/MW gp140
We calculated percent competition of MAb1 and MAb2
rom MR using the following formula (2):
Competition
5 ~1 2 MR MAb2 after blocking with MAb1/MR
MAb2 without MAb1 blocking! 3 100
This formula was used to eliminate the variation of
Ab2 response due to variability of captured gp140
bserved in different competition cycles.
eactivities of MAbs with mutated gp120 molecules
Plasmids expressing the following mutated gp120 mol-
cules were provided by J. Sodroski (22, 36): 88N/P,
02E/L, 113D/A, 117K/W, 256S/Y, 257T/G, 368D/P, 368D/E,
70E/R, 381E/P, 421K/L, 427W/S, 457D/E, 475M/S, DV1,
V1/V2, DV3, and pTat. Env proteins were expressed by
OS7 cells that had been electroporated with the above
lasmids. COS7 cells were maintained in DMEM-10 (Dul-
ecco’s modified Eagle’s medium containing 10% FBS)
nd used during logarithmic growth. After trypsinization,
ells were washed twice with PBS and suspended at 2 3
06 cells/ml. Cells (0.5 ml) were transferred into a chilled
.4-mm electroporation cuvette (InVitrogen). A mixture of
0 mg of plasmid expressing gp120, 20 mg of plasmid
xpressing Tat, and 20 mg of salmon sperm DNA (Strat-
gene, La Jolla, CA) was added to the cell suspension
nd incubated for 10 min on ice. After electroporation,
he cells were incubated on ice for 10 min and trans-
erred into 100-mm-diameter culture dishes (Corning,
Y). After 24 h, the culture medium was replaced with
resh DMEM-10, and supernatants were harvested at
2 h after transfection.
A capture ELISA, modified from Moore et al. (17), was
sed to determine the reactivities of the MAbs with the
utant gp120 env proteins. Immulon II plates (Dynatec
aboratory, VA) were coated overnight with 100 ml of
heep polyclonal antibody to the C-terminus of gp120International Enzymes, Inc., CA) at 2 mg/ml in sodiumarbonate buffer (pH 9.0). The plates were blocked with
% milk in PBS for 1 h. To capture the gp120 proteins, 100
l of transfected culture supernatants was added to the
ells and incubated for 2 h at room temperature. A MAb
20 mg/ml) or rabbit serum 2144 (1:200 dilution) was
dded and incubated for 1 h. Bound antibody was de-
ected with peroxidase-conjugated anti-mouse or anti-
abbit IgG and 2,29-amino-did-[3-ethylbenzthiazolinesul-
onate (6)] substrate (Boehringer-Mannheim Biochemi-
als). To determine the binding efficiency of an MAb to
p120, the following formula was used:
A405 ~MAb bound to mutant gp120!
405 ~MAb bound to wild-type gp120!
3
A405 ~2144 bound to wild-type gp120!
A405 ~2144 bound to mutant gp120!
Values of ,0.5 were considered to represent a signif-
cant reduction in binding.
eutralization of HIV-1 by MAbs
The abilities of MAbs to neutralize HIV-1 (NL4–3) were
etermined using virus grown in Jurkat cells as follows.
urkat cells were adjusted to 1 3 106 cells/ml in RPMI
640 containing 10% FBS, 300 mM L-glutamine, and an-
ibiotics. Cells (200 ml) were seeded onto wells of 96-well
lates. Serial 2-fold dilutions of MAb were prepared
anging from 100 to 6.25 mg/ml. MAbs (22 ml) were mixed
ith 22 ml of NL4–3 (2.0 3 104 TCID50/ml) in microcen-
rifuge tubes and incubated for 2 h at 37°C. Then 10 ml of
Ab–virus mixture was used to infect Jurkat cells in
ndividual wells containing 1 3 105 cells. All MAb–virus
ixtures were performed in quadruplicate. Cultures
ere maintained for 2 weeks with a half-medium change
n day 7. On day 14, media were collected and assayed
or reverse transcriptase activity (34). The MAb concen-
ration required to achieve 50% was calculated with use
f the formula of Reed and Muench (26).
ACKNOWLEDGMENTS
We thank Norman Cooper for cells and viruses and Richard Wyatt
nd Joseph Sodroski for plasmids expressing mutant gp120 env pro-
eins. MAb F105, obtained through the AIDS Research and Reference
eagent Program, Division of AIDS, NIAID, was contributed by Marshall
osner.
REFERENCES
1. Broder, C. C., and Berger, E. A. (1993). CD4 molecules with a
diversity of mutations encompassing the CDR3 region efficiently
support human immunodeficiency virus type 1 envelope glyco-
protein-mediated cell fusion. J. Virol. 67, 913–926.
2. Broder, C. C., and Berger, E. A. (1995). Fusogenic selectivity of the
envelope glycoprotein is a major determinant of human immu-
nodeficiency virus type 1 tropism for CD41 T-cell lines vs.
primary macrophages. Proc. Natl. Acad. Sci. USA 92, 9004–
9008.
11
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
3
3
3
3
266 SUGIURA ET AL.3. Broder, C. C., Earl, P. L., Long, D., Moss, B., and Doms, R. W. (1994).
Antigenic implications of HIV-1 env quaternary structure. Proc.
Natl. Acad. Sci. USA 91, 11699–11703.
4. Choe, H.-R., and Sodroski, J. (1995). Adaptation of human immuno-
deficiency virus type 1 to cells expressing a binding-deficient
CD4 mutant (lysine 46 to aspartic acid). J. Virol. 69, 2801–2810.
5. Daiss, J. L., and Scalice,. E. R. (1994). “Epitope Mapping on BIAcore:
Theoretical and Practical Considerations,” pp. 143–156, A com-
panion to Methods in Enzymology, vol. 6. New York, Academic
Press, Inc.
6. Doms, R. W., and Moore, J. P. (1997). HIV-1 Coreceptor use: A
molecular window into viral tropism. In “Human Retroviruses
and AIDS” (B. Korber, B. Foley, T. Leitner, F. McCutchan, B. Hahn,
J. W. Mellors, G. Myers, and C. Kuilen, eds.), Los Alamos, New
Mexico.
7. Earl, P. L., Broder, C. C., Doms, R. W., and Moss, B. (1997). Epitope
map of human immunodeficiency virus type-1 gp41 derived from
47 monoclonal antibodies produced by immunization with oli-
gomeric envelope protein. J. Virol. 71, 2674–2684.
8. Earl, P. L., Broder, C. C., Long, D., Lee, S. A., Peterson, J.,
Chakrabarti, S., Doms, R. W., and Moss, B. (1994). Native oligo-
meric forms of human immunodeficiency virus type 1 envelope
glycoprotein elicit a diverse array of monoclonal antibody reac-
tivities. J. Virol. 68, 3015–3026.
9. Fouts, T. R., Binley, J. M., Trkola, A., Robinson, J. E., and Moore, J. P.
(1997). Neutralization of the human immunodeficiency virus type
1 primary isolate JR-FL by human monoclonal antibodies corre-
lates with antibody binding to the oligomeric form of the enve-
lope glycoprotein complex. J. Virol. 71, 2779–2785.
0. Fouts, T. R., Trkola, A., Fung, M. S., and Moore, J. P. (1998). Inter-
actions of polyclonal and monoclonal anti-glycoprotein 120 an-
tibodies with oligomeric glycoprotein 120-glycoprotein 41 com-
plexes of a primary HIV type 1 isolate: relationship to neutral-
ization. AIDS Res. Human Retrov. 14, 591–597.
1. Fuerst, T. R., Niles, E. G., Studier, F. W., and Moss, B. (1986).
Eukaryotic transient-expression system based on recombinant
vaccinia virus that synthesizes bacteriophage T7 RNA polymer-
ase. Proc. Natl. Acad. Sci. USA 83, 8122–8126.
2. Ho, D. D., McKeating, J. A., Li, S. L., Moudgil, T., Daar, E. S., Sun,
N.-C., and Robinson, J. E. (1991). Conformational epitope on
gp120 important in CD4 binding and human immunodeficiency
virus type 1 neutralization identified by a human monoclonal
antibody. J. Virol. 65, 489–493.
3. Koito, A., Stamatatos, L., and Cheng-Mayer, C. (1995). Small amino
acid sequence changes within the V2 domain can affect the
function of a T-cell line- tropic human immunodeficiency virus
type 1 envelope gp120. Virology 206, 878–884.
4. Kwong, P. D., Wyatt, R., Robinson, J., Sweet, R. W., Sodroski, J., and
Hendrickson, W. A. (1998). Structure of an HIV gp120 envelope
glycoprotein in complex with the CD4 receptor and a neutraliz-
ing human antibody. Nature 393, 648–659.
5. Moore, J. P., Cao, Y., Qing, L., Sattentau, Q. J., Pyati, J., Koduri, R.,
Robinson, J., Barbas, C. F., III, Burton, D. R., and Ho, D. D. (1995).
Primary isolates of human immunodeficiency virus type 1 are
relatively resistant to neutralization by monoclonal antibodies to
gp120 and their neutralization is not predicted by studies with
monomeric gp120. J. Virol. 69, 101–109.
6. Moore, J. P., and Ho, D. D. (1993). Antibodies to discontinuous or
conformationally sensitive epitopes on the gp120 glycoprotein
of human immunodeficiency virus type 1 are highly prevalent in
sera of infected humans. J. Virol. 67, 863–875.
7. Moore, J. P., and Jarret, R. F. (1988). Sensitive ELISA for the gp120
and gp160 surface glycoprotein of HIV-1. AIDS Res. Human
Retrov. 4, 369–379.
8. Moore, J. P., Sattentau, Q. J., Wyatt, R., and Sodroski, J. (1994).
Probing the structure of the human immunodeficiency virus 3surface glycoprotein gp120 with a panel of monoclonal antibod-
ies. J. Virol. 68, 469–484.
9. Moore, J. P., and Sodroski, J. (1996). Antibody cross-competition
analysis of the human immunodeficiency virus type 1 gp120
exterior envelope glycoprotein. J. Virol. 70, 1863–1872.
0. Moore, J. P., Thali, M., Jameson, B. A., Vignaus, F., Lewis, G. K.,
Poon, S.-W., Charles, M., Fung, M. S., Sun, B., Durda, P. J.,
Akerblom, L., Wahren, B., Ho, D. D., Santtentau, Q. J., and
Sodroski, J. (1993). Immunochemical analysis of the gp120
surface glycoprotein of human imunodeficiency virus type 1:
Probing the structure of the C4 and V4 domains and the
interaction of the C4 domain with the V3 loop. J. Virol. 67,
4785–4796.
1. Moore, J. P., Willey, R. L., Lewis, G. K., Robinson, J., and Sodroski, J.
(1994). Immunological evidence for interactions between the
first, second, and fifth conserved domains of the gp120 surface
glycoprotein of human immunodeficiency virus type 1. J. Virol.
68, 6836–6847.
2. Olshevsky, U., Helseth, E., Furman, C., Li, J., Haseltine, W., and
Sodroski, J. (1990). Identification of individual human immuno-
deficiency virus type 1 gp120 amino acids important for CD4
receptor binding. J. Virol. 64, 5701–5707.
3. Otteken, A., Earl, P. L., and Moss, B. (1996). Folding, assembly, and
intracellular trafficking of the human immunodeficiency virus
type 1 envelope glycoprotein analyzed with monoclonal antibod-
ies recognizing maturational intermediates. J. Virol. 70, 3407–
3415.
4. Parren, P. W. H. I., Mondor, I., Naniche, D., Ditzel, H. J., Klasse, P. J.,
Burton, D. R., and Sattentau, Q. J. (1998). Neutralization of human
immunodeficiency virus type 1 by antibody to gp120 is deter-
mined primarily by occupancy of sites on the virion irrespective
of epitope specificity. J. Virol. 72, 3512–3519.
5. Posner, M. R., Hideshima, T., Cannon, T., Mukherjee, M., Mayer,
K. H., and Byrn, R. A. (1991). An IgG human monoclonal antibody
that reacts with HIV-1/gp120, inhibits virus binding to cells, and
neutralizes infection. J. Immunol. 146, 4325–4332.
6. Reed, L. J., and Muench, H. (1938). A simple method of estimating
fifty percent endpoints. Am. J. Hyg. 27, 493–497.
7. Richardson, T. M., Jr., Broder, C. C., Hoxie, J. A., Mascola, J. R., Earl,
P. L., and Doms, R. W. (1996). The humoral response to oligo-
meric human immunodeficiency virus type I envelope protein.
J. Virol. 70, 753–762.
8. Sattentau, Q. J., and Moore, J. P. (1995). Human immunodeficiency
virus type 1 neutralization is determined by epitope exposure on
the gp120 oligomer. J. Exp. Med. 182, 185–196.
9. Sattentau, Q. J., Zolla-Pazner, S., and Piognard, P. (1995). Epitope
exposure on functional, oligomeric HIV-1 gp41 molecules. Virol-
ogy 206, 713–717.
0. Stamatatos, L., and Cheng-Meyer, C. (1993). Evidence that the
structural conformation of envelope gp120 affects human immu-
nodeficiency virus type 1 infectivity, host range, and syncytium-
forming ability. J. Virol. 67, 5635–5639.
1. Steimer, K. S., Scandella, C. J., Skiles, P. V., and Haigwood, N. L.
(1991). Neutralization of divergent HIV-1 isolates by conforma-
tion-dependent human antibodies to gp120. Science 254, 105–
108.
2. Thali, M., Furman, C., Ho, D. D., Robinson, J., Tilley, S., Pinter, A.,
and Sodroski, J. (1992). Discontinuous, conserved neutralization
epitopes overlapping the CD4-binding region of human imuno-
deficiency virus type 1 gp120 envelope glycoprotein. J. Virol. 66,
5635–5641.
3. Weissenhorn, W., Wharton, S. A., Calder, L. J., Earl, P., Moss, B.,
Skehel, J. J., and Wiley, D. C. (1996). The ectodomain of HIV-1 env
subunit gp41 forms a soluble, alpha-helical, rod-like oligomer in
the absence of gp120 and the N-terminal fusion peptide. EMBO
J. 15, 1507–1514.4. Willey, R. L., Smith, D. H., Lasky, L. A., Theodore, T. S., Earl, P. L.,
33
3
3
267CONFORMATION-DEPENDENT MAbs TO HIV-1 gp120Moss, B., Capon, D. J., and Martin, M. A. (1988). In vitro mu-
tagenesis identifies a region within the envelope gene of the
human immunodeficiency virus that is critical for infectivity.
J. Virol. 62, 139–147.
5. Wyatt, R., Kwong, P. D., Desjardins, R., Sweet, R. W., Robinson, J.,
Hendrickson, W. A., and Sodroski, J. G. (1998). The antigenic
structure of the HIV gp120 envelope glycoprotein. Nature 393,
705–711.
6. Wyatt, R., Moore, J., Accola, M., Desjardin, E., Robinson, J., and
Sodroski, J. (1995). Involvement of the V1/V2 variable loop struc-
ture in the exposure of human immunodeficiency virus type 1gp120 epitopes indiced by receptor binding. J. Virol. 69, 5723–
5733.
7. Wyatt, R., Sullivan, N., Thali, M., Repke, H., Ho, D., Robinson, J.,
Posner, M., and Sodroski, J. (1993). Functional and immunolog-
ical characterization of human immunodeficiency virus type 1
envelope glycoproteins containing deletions of the major vari-
able region. J. Virol. 67, 4557–4565.
8. Wyatt, R., Thali, M., Tilley, S., Pinter, A., Posner, M., Ho, D., Robin-
son, J., and Sodroski, J. (1992). Relationship of the human im-
munodeficiency virus type 1 gp120 third variable loop to ele-
ments of the CD4 binding site. J. Virol. 66, 6997–7004.
